| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.31.12.37S |
| P8608 | Fatcat ID | release_hum2oisri5gvzevmsheqdjwyra |
| P698 | PubMed publication ID | 22122221 |
| P2093 | author name string | Cara Liday | |
| P2860 | cites work | Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes | Q44003021 |
| Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting | Q45103575 | ||
| The role of the community pharmacist in fulfilling information needs of patients starting oral antidiabetics. | Q45922907 | ||
| Management of patients with type 2 diabetes by pharmacists in primary care clinics | Q47926739 | ||
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials | Q33785313 | ||
| Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial | Q33804791 | ||
| Long-term effects of intensive glucose lowering on cardiovascular outcomes | Q33851861 | ||
| Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial | Q34421951 | ||
| Standards of medical care in diabetes--2011. | Q34425055 | ||
| Clinical inertia | Q34428121 | ||
| The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus | Q36894297 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial | Q37400845 | ||
| Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 | ||
| Evaluating categorisation and clinical relevance of drug-related problems in medication reviews | Q37734953 | ||
| Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. | Q37762263 | ||
| Clinical inertia in management of T2DM. | Q37780870 | ||
| Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials | Q37866586 | ||
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card | Q41824843 | ||
| New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals | Q42171251 | ||
| Severe hypoglycemia and risks of vascular events and death | Q42868535 | ||
| An employer-based, pharmacist intervention model for patients with type 2 diabetes | Q43172609 | ||
| P433 | issue | 12 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| pharmacology | Q128406 | ||
| P304 | page(s) | 37S-43S | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus | |
| P478 | volume | 31 |
| Q38219485 | Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy |
| Q33706752 | Effect of medicinal mushrooms on blood cells under conditions of diabetes mellitus |
| Q28250844 | Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin |
Search more.